SAN DIEGO, CA--(Marketwired - Jun 13, 2016) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company's top line results from its RecalMax™ U.S. four month human survey use clinical trial in people with low memory and learning.

RecalMax™ use resulted in the following:

1. 115% increase in the recall of words and names
2. 49.5% increase in maintaining thoughts when distracted
3. 35% increase in processing speed

About the RCM-001 Use Survey Trial:

• Method: Scores were assessed at initiation of trial, midpoint and conclusion. A five‐point satisfaction scale was used. Satisfaction was summarized by combining scores from Mostly Satisfied, Satisfied, and Very Satisfied. Dissatisfaction was summarized using results from Dissatisfied and Very Dissatisfied.
• Subjects: 72 patients completed the trial in the United States.
• Age: Over 50% of participants who completed the trial were between the ages of 40‐59. Over 70% were age 40 and older. This was true at baseline as well.
• Regimen: One capsule twice a day for a total of 16 weeks.
  
  

Pursuant to these clinical trials, the data indicate that RecalMax™ was very well tolerated with no serious adverse events reported. The only minor events reported were dry mouth that was resolved by drinking 62 ounce of water daily and sleep disturbance, if taken in the late afternoon.

RecalMax™ is a proprietary oral low dose formulation of Arginine and Citrulline with the natural absorption enhancer Bioperine®. RecalMax™ was formulated to increase blood flow and nitric oxide production.

"We are thrilled about these results from the RecalMax™ use trial which confirms that positive activity of the product and opens an additional $3 billion market for the company," said Dr. Bassam Damaj, President & CEO of Innovus Pharma. "Memory and learning loss are major issues with diseases such as Alzheimer in aging population, and providing a natural product clinically tested to increase memory and learning to help brain health is a big step in managing the daily lives of the 5 million people in the U.S. and 26 million worldwide suffering from such conditions."

"Having clinical data showing improvement in memory and learning differentiates RecalMax™ from the rest of the products on the market and gives it the credibility needed to make a strong entry in to the market," added Dr. Damaj.

The Company expects to launch the product in Q3 2016.

About RecalMax™
RecalMax™ is a proprietary, novel oral dietary supplement to maximize nitric oxide's beneficial effects on brain health. RecalMax™ contains a patented formulation of low dose L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine®.
www.recalmax.com

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize Vesele® and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.